KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Long-Term Deferred Tax (2016)

Neogenomics (NEO) has disclosed Long-Term Deferred Tax for 3 consecutive years, with $6.5 million as the latest value for Q4 2016.

  • For the quarter ending Q4 2016, Long-Term Deferred Tax rose 120.06% year-over-year to $6.5 million, compared with a TTM value of $6.5 million through Dec 2016, up 120.06%, and an annual FY2016 reading of $6.5 million, up 120.06% over the prior year.
  • Long-Term Deferred Tax was $6.5 million for Q4 2016 at Neogenomics, up from -$32.4 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $6.5 million in Q4 2016 and bottomed at -$32.4 million in Q4 2015.
  • Average Long-Term Deferred Tax over 3 years is -$8.5 million, with a median of $320000.0 recorded in 2014.
  • The sharpest move saw Long-Term Deferred Tax plummeted 10227.81% in 2015, then soared 120.06% in 2016.
  • Year by year, Long-Term Deferred Tax stood at $320000.0 in 2014, then tumbled by 10227.81% to -$32.4 million in 2015, then surged by 120.06% to $6.5 million in 2016.
  • Business Quant data shows Long-Term Deferred Tax for NEO at $6.5 million in Q4 2016, -$32.4 million in Q4 2015, and $320000.0 in Q4 2014.